Design Therapeutics Maps H2 Data Readouts for RESTORE-FA, FECD Biomarker Study and DM1 Program [Yahoo! Finance]
Design Therapeutics, Inc. (DSGN)
Company Research
Source: Yahoo! Finance
protein, including muscle biopsy) after 12 weeks of dosing, with topline data expected in the second half of the year Design is running an exploratory FECD Phase 2 biomarker study using discarded corneal tissue to assess splicing engagement and expects results H2, while its DM1 candidate DT-818 is a differentiated small-molecule approach that showed 90% reduction in toxic DMPK RNA preclinically and is bioavailable IV and sub-Q. The company has over $200 million in cash, which management says funds the plan into 2029 with the goal of achieving positive clinical proof-of-concept in at least one program. Interested in Design Therapeutics, Inc.? Here are five stocks we like better. Design Therapeutics (NASDAQ:DSGN) outlined its near-term clinical priorities and key upcoming data readouts during a conference discussion with Leerink Partners' Joe Schwartz, featuring comments from CEO Pratik Shah. The conversation focused on the company's Friedreich's ataxia (FA) program, ongoing wor
Show less
Read more
Impact Snapshot
Event Time:
DSGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DSGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DSGN alerts
High impacting Design Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DSGN
News
- Design Therapeutics (DSGN) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating and a $15.00 price target on the stock.MarketBeat
- Design Therapeutics (DSGN) had its price target raised by Royal Bank Of Canada from $13.00 to $14.00. They now have an "outperform" rating on the stock.MarketBeat
- Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates [Yahoo! Finance]Yahoo! Finance
- Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business UpdatesGlobeNewswire
- Design Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
DSGN
Earnings
- 3/9/26 - Beat
DSGN
Sec Filings
- 3/11/26 - Form SCHEDULE
- 3/9/26 - Form S-8
- 3/9/26 - Form 10-K
- DSGN's page on the SEC website